At the 61st ASH Annual Meeting & Exposition, Deepa Manwani discusses her presentation: Moving From Science Fiction to Clinical Reality: Gene Therapy for Beta-Hemoglobinopathies.
1. What is the rationale for gene therapy for beta-hemoglobinopathies and sickle cell disease?
2. What have been the most important recent advances in gene therapies for beta-hemoglobinopathies and sickle cell disease? (1:10)
3. What are the major challenges of translating clinical trial findings into real world use? (2:30)
4. What are the limitations of emerging strategies and how can outcomes be further improved? (3:21)
5. The high cost of gene therapy is a major barrier to its widespread application. How can this be overcome? (4:52)
Deepa Manwani has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Haematology
Steven Pipe, ASH 2020 – First Results from the HOPE-B Gene Therapy Trial
We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract ‘First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe […]
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis. Questions: What are the major therapeutic […]
George Goshua, EHA 2020: Endotheliopathy is Essential in COVID-19 Associated Coagulopathy
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19. Questions: 1. How common is coagulopathy in COVID-19 infection and who is at greatest risk? (0:03) 2. What is known about the role of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!